ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Abstract Background Escherichia coli (E. coli) is a pathogen of great concern in immunosuppressed patients. While antimicrobial prophylactic therapy has become the standard, the emergence of resistant pathogens has some questioning its use. This study describes our experience with E.coli as a pa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2049 |
| _version_ | 1819005060187684864 |
|---|---|
| author | Daniel Olson Abraham Tareq Yacoub Gelenis Domingo John Norman Greene |
| author_facet | Daniel Olson Abraham Tareq Yacoub Gelenis Domingo John Norman Greene |
| author_sort | Daniel Olson |
| collection | DOAJ |
| description | Abstract
Background
Escherichia coli (E. coli) is a pathogen of great concern in immunosuppressed patients. While antimicrobial prophylactic therapy has become the standard, the emergence of resistant pathogens has some questioning its use. This study describes our experience with E.coli as a pathogen in neutropenic patients with a hematologic malignancy, and addresses future directions of treatment for this patient population.
Methods
A retrospective chart review of 245 E.coli bacteremia patients at Moffitt Cancer Center from 05/18/02 – 05/15/12 was conducted. Patients were identified via microbiology laboratory computerized records.
Results
The included patients experienced clinically significant E.coli bacteremia resulting in a median hospital stay of 14.7 days. Several patients developed severe sepsis requiring the use of pressor and ventilator therapy.
Conclusions
E.coli is a major pathogen in these patient populations resulting in extended hospital stays and specialized treatment to overcome their E.coli bacteremia. The data supports the use of fluoroquinolone prophylactic therapy, however, earlier detection and treatment of neutropenic infection is needed. |
| first_indexed | 2024-12-20T23:46:47Z |
| format | Article |
| id | doaj.art-8013003daab44d4294c4d3b6ff957428 |
| institution | Directory Open Access Journal |
| issn | 2035-3006 |
| language | English |
| last_indexed | 2024-12-20T23:46:47Z |
| publishDate | 2014-08-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj.art-8013003daab44d4294c4d3b6ff9574282022-12-21T19:22:56ZengMattioli1885Mediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-0161e2014068e201406810.4084/mjhid.2014.0681505ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIESDaniel Olson0Abraham Tareq Yacoub1Gelenis Domingo2John Norman Greene3University of South Florida Morsani College of Medicine 12901 Bruce B Downs Blvd, Tampa, FL 33612Moffitt Cancer CenterAssistant Member, Internal and Hospital Medicine Program Moffitt Cancer Center and Research Institute 12902 Magnolia Drive Tampa, FL 33612-9497Section Chief, Division of Infectious Diseases and Tropical Medicine - Moffitt Cancer Center, Tampa FL Professor of MedicineAbstract Background Escherichia coli (E. coli) is a pathogen of great concern in immunosuppressed patients. While antimicrobial prophylactic therapy has become the standard, the emergence of resistant pathogens has some questioning its use. This study describes our experience with E.coli as a pathogen in neutropenic patients with a hematologic malignancy, and addresses future directions of treatment for this patient population. Methods A retrospective chart review of 245 E.coli bacteremia patients at Moffitt Cancer Center from 05/18/02 – 05/15/12 was conducted. Patients were identified via microbiology laboratory computerized records. Results The included patients experienced clinically significant E.coli bacteremia resulting in a median hospital stay of 14.7 days. Several patients developed severe sepsis requiring the use of pressor and ventilator therapy. Conclusions E.coli is a major pathogen in these patient populations resulting in extended hospital stays and specialized treatment to overcome their E.coli bacteremia. The data supports the use of fluoroquinolone prophylactic therapy, however, earlier detection and treatment of neutropenic infection is needed.http://www.mjhid.org/index.php/mjhid/article/view/2049: Escherichia ColiNeutropeniaBone Marrow TransplantHematological Malignancy |
| spellingShingle | Daniel Olson Abraham Tareq Yacoub Gelenis Domingo John Norman Greene ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES Mediterranean Journal of Hematology and Infectious Diseases : Escherichia Coli Neutropenia Bone Marrow Transplant Hematological Malignancy |
| title | ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES |
| title_full | ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES |
| title_fullStr | ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES |
| title_full_unstemmed | ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES |
| title_short | ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES |
| title_sort | escherichia coli an important pathogen in patients with hematologic malignancies |
| topic | : Escherichia Coli Neutropenia Bone Marrow Transplant Hematological Malignancy |
| url | http://www.mjhid.org/index.php/mjhid/article/view/2049 |
| work_keys_str_mv | AT danielolson escherichiacolianimportantpathogeninpatientswithhematologicmalignancies AT abrahamtareqyacoub escherichiacolianimportantpathogeninpatientswithhematologicmalignancies AT gelenisdomingo escherichiacolianimportantpathogeninpatientswithhematologicmalignancies AT johnnormangreene escherichiacolianimportantpathogeninpatientswithhematologicmalignancies |